Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arry-797. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arry-797 SCHEMBL31046796 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| Arry-797 SCHEMBL29351662 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| Arry-797 SCHEMBL222635 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| SCHEMBL31371686 | 0.92 | MAPK14 (0.85) | MAPK14BRD4ACKR3CDK2CDK1 | |
| SCHEMBL31371552 | 0.90 | MAPK14 (0.81) | MAPK14CDK2CDK1HTR2AHTR2C | |
| SCHEMBL2443328 | 0.90 | MAPK14 (0.81) | MAPK14CDK2CDK1HTR2AHTR2C | |
| SCHEMBL15034375 | 0.90 | MAPK14 (0.81) | MAPK14HTR2AHTR2CMETKDR | |
| SCHEMBL12329316 | 0.88 | MAPK14 (0.79) | MAPK14BRD4HTR2AHTR2CALDH1A1 | |
| SCHEMBL13180094 | 0.88 | MAPK14 (0.79) | MAPK14BRD4HTR2AHTR2CALDH1A1 | |
| SCHEMBL2448270 | 0.87 | MAPK14 (0.77) | MAPK14BRD4HTR2AHTR2CMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| CN-118105493-A | Skeletal muscle generation inducer, pharmaceutical composition, kit and application thereof | 北京大学 | 2024-05-31 | — | — | CN | claimed |
| US-20240156816-A1 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. | 2024-05-16 | — | — | US | claimed |
| US-11844800-B2 | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-19 | — | — | US | claimed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2023-08-24 | — | — | US | claimed |
| EP-4196120-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | Kinarus AG (CH) | 2023-06-21 | — | — | EP | claimed |
| WO-2023280911-A1 | P38-INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | Westfälische Wilhelms-Universität Münster (DE) | 2023-01-12 | — | — | WO | claimed |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | UNIVERSITÉ PARIS CITÉ (FR) | 2022-09-29 | — | — | US | claimed |
| CN-115105601-A | Pharmaceutical combination for the treatment of cancer | 投资支持有限公司 | 2022-09-27 | — | — | CN | claimed |
| EP-4051665-A1 | SOLID STATE FORMS OF ARRY-797 AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-09-07 | — | — | EP | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-20220175786-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SUPPORT-VENTURE GMBH (CH) | 2022-06-09 | — | — | US | claimed |
| EP-3980012-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-04-13 | — | — | EP | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| WO-2022034031-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2022-02-17 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | PDE5A, PRKG2, MAPKAPK5 | MAPK14 19/4885BRD4 2942/4885ACKR3 1337/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885BRD4 577/4885ACKR3 1258/4885 |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | PPARA, PPARD, PPARG | MAPK14 85/4885BRD4 365/4885ACKR3 337/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | MAPK14 3891/4885BRD4 4/4885ACKR3 3728/4885 |
| US-20220175786-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | PPARG, PPARA, PPARD | MAPK14 81/4885BRD4 362/4885ACKR3 490/4885 |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | NRP1, MAPK1, MAPKAP1 | MAPK14 97/4885BRD4 3331/4885ACKR3 1170/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885BRD4 1570/4885ACKR3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.